{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-25-000099","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.098209+00:00","generated_at":"2026-05-24T22:52:06.288676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KORU Medical reports record Q4 revenue of $8.8M (+23% YoY); issues 2025 guidance $38-39M","bullets":["Q4 net revenue $8.8M (+23% YoY); full year $33.6M (+18% YoY).","Q4 gross margin 62.9% (+260 bps); full year 63.4% (+480 bps).","Net loss improved to $1.6M (Q4) and $6.1M (full year); adjusted EBITDA loss narrowed.","Cash $9.6M at Dec 31; Q4 cash flow positive $0.8M; 2025 guidance: revenue $38-39M, gross margin 61-63%, operational cash flow positive.","Novel Therapies segment renamed Pharma Services and Clinical Trials (PST), effective Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-25-000099","json":"https://secwatch.observer/filing/0001161697-25-000099.json","markdown":"https://secwatch.observer/filing/0001161697-25-000099.md","text":"https://secwatch.observer/filing/0001161697-25-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169725000099/0001161697-25-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169725000099/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:52:06.288676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}